AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03453086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block(TPVB) group
Description: Thoracic paravertebral block group (TPVB) group: The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes.Tuohy needle will be introduced in a cephalad direction. The tip of the needle will be advanced under direct visualization until it pierces the superior costo-transverse ligament. When the needle tip is located immediately above the pleura, the needle is aspirated to confirm the absence of blood or air.~Serratus anterior plane block group (SAP) group: The US probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the 5th rib is identified in the midaxillary line. The latissimus dorsi, teres major and serratus muscles will be then easily identifiable by US overlying the fifth rib. The needle will be introduced in-plane with respect to the US probe from supero-anterior to postero-inferior
Study NCT01538173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250ml HES 6%
Description: Application twice a day 250ml HES 6% for three days postoperatively.
Study NCT01538173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 9% NaCl 500ml
Description: Application twice a day 500ml 9% NaCl for three days postoperatively.
Study NCT03163030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Description: Electrical Stimulation of the Vagus Nerve
Study NCT01948310 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Aerobic exercise 3 times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold (heart rate at which angina symptoms began on the stress test)
Study NCT01948310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of placebo twice per day vs. Ranolazine 1000mg twice per day
Study NCT03067831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: Transplantation of purified autologous bone marrow-derived stem cells.
Study NCT02128581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39
Description: use Exendin-9,39 @ 750pmol/kg/min and Exendin-9,39 @ 300pmol/kg/min to block endogenous GLP-1 in humans after gastric bypass and determine contribution of GLP to satiety after meal ingestion
Study NCT02128581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT03340805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer
Description: LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5).
Study NCT03340805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride.
Study NCT04541342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: initial arthroscopy with medial opening-wedge high tibial osteotomy fixed by a plate system then second look arthroscopy with plate removal
Description: It is a joint preserving procedure especially preferred in young patients for whom arthroplasty is not desirable. The procedure promotes regeneration by causing lateral shift of the weight-bearing axis, thus decreasing load on the medial compartment and widening the medial joint space.Many of the patients complains of irritation through the plate and wish metal removal after healing of the osteotomy.All patients will undergo initial arthroscopy before high tibial osteotomy (HTO). During arthroscopy, debridement of the degenerate tissues and meniscal tears if present will be performed. Then opening-wedge high tibial osteotomy (OWHTO) will be performed and fixed by a plate system. Second-look arthroscopy will be conducted at the time of plate removal after healing of the osteotomy. This will be after about 6 months up to one year.
Study NCT05862441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV2-SA2
Description: AV2 is a combination of FDA GRAS-label approved organic compounds (natural essential oils: carvone, eugenol, geraniol, and nerolidol) that is postulated to be able to prevent viral entry and proliferation by deactivating the infectious virions before they enter the cell. Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis. Implementation of AV2-SA combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.
Study NCT05862441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SA
Description: Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis.
Study NCT00487279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillator
Description: ICD(Implantable Cardioverter Defibrillator)
Study NCT00487279 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No Intervention
Study NCT04344834 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: A questionnaire or scales
Description: A questionnaire or scale to assess the participants mental health.
Study NCT02873221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Study NCT02873221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching Ubrogepant
Description: Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.
Study NCT02873221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
Study NCT01205581 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone High Dose Vaccine
Description: Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.
Study NCT01205581 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone Standard Dose Vaccine
Description: Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.
Study NCT03645018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: diagnosis with tomosynthesis
Description: Re-evaluation of lung nodule detection rate at 5 years in patients with early diagnosis of lung cancer
Study NCT02425072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A plus chemotherapy
Description: NovoTTF-100A System with Physician's Choice Chemotherapy
Study NCT03007108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood withdrawal
Study NCT00841373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation
Description: Panretinal Photocoagulation treatment
Study NCT00841373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation and intravitreal injection of ranibizumab
Description: Panretinal photocoagulation and ranibizumab
Study NCT03238846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three month dispensing of ART in CARGs
Description: Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 3 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
Study NCT03238846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six month dispensing of ART in CARGs
Description: Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 6 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
Study NCT00827580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eniluracil
Study NCT02129218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.
Study NCT02129218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.
Study NCT03548194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNC210
Description: BNC210 300 mg b.i.d
Study NCT03548194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo b.i.d.
Study NCT03850522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 peptide
Description: PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.
Study NCT00838136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine 25 mg Chewable Tablets
Description: 2 x 25 mg, single-dose fed
Study NCT00838136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal® 25 mg Chewable Tablets
Description: 2 x 25 mg, single-dose fed
Study NCT01805570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: 25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI. The loading dose of Prasugrel will be 60 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
Study NCT01805570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI. The loading dose of Ticagrelor will be 360 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
Study NCT03815604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Independent Housing and Support (IHS)
Description: Direct placement of people with SMI in an independent accommodation in the community, usually in a flat rented by the service user. Support is provided by a coach according to individual needs in a permanent housing situation without time limit.
Study NCT03815604 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Residential Care Settings and other Treatment as Usual (RCS/TAU)
Description: Placement in a common residential home or supportive housing setting with the aim to gain psycho-social stability before being able to maintain independent housing.
Study NCT01438944 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicabate 21mg transdermal NRT
Description: Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.
Study NCT02799290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADIPOSE TISSUE EXTRACT
Description: Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration
Study NCT02799290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLATELET-RICH PLASMA GEL
Description: Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions
Study NCT02194088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac and Atropine combination drug
Description: Diclofenac will be associated with a small dose of atropine 1.2mg
Study NCT02194088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For each capsule of active medication, a capsule of placebo will be provided, identical looking.
Study NCT01429935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginger powder
Description: capsules contain 500mg Ginger powder,every 6hours,for 5 days
Study NCT01429935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: capsules of Ibuprofen 400 mg, every 6 hours for 5 days
Study NCT03785873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous (IV) infusion
Study NCT03785873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal-Irinotecan
Description: Intravenous (IV) infusion
Study NCT03785873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Intravenous (IV) infusion
Study NCT03785873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenous (IV) infusion
Study NCT02502422 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Classic laryngeal mask airway
Description: 1. measurement of head and neck~   * Ht,Wt,BMI, neck circumference above a thyroid cartilage, mandible circumference( from the lower part of earlobe-mandible angle-mentum-mandible angle to the lower part of earlobe), neck length (mastoid tip\~sternal notch), modified mallampati classification under sitting position, thyromental distance.~2. laryngeal mask airway insertion and measuring cuff pressure by pressure transducer~   * # 4.0 for female, #5.0 for male~  * initial cuff volume(air) : maximum volume recommended by the manufacturer~  * check pressure : if it exceed 60cmH20, we will remove air until 60cmH20~  * remove air until gas leak occured around the cuff under airway pressure 15cmH20, fresh gas flow 6liters/min. Check the volume and pressure just before leakage occured.
Study NCT03129438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: continuous EEG (cEEG)
Description: differential use of continuous versus routine EEG
Study NCT03129438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: routine EEG (rEEG)
Description: differential use of continuous versus routine EEG
Study NCT01725763 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac MRI
Study NCT05710874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPP-ACP paste
Description: Daily application of CPP-ACP (Casein phosphopeptide amorphous calcium phosphate) paste (Tooth Mousse®) in addition to twice daily use of conventional toothpaste.
Study NCT05710874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPP-ACPF paste
Description: Daily application of CPP-ACPF (Casein phosphopeptide amorphous calcium phosphate in combination with fluoridepaste) (MI Paste Plus®) in addition to twice daily use of conventional toothpaste.
Study NCT05710874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.25% fluoride gel
Description: Weekly application of 1.25% fluoride gel (Elmex Medical Gel®) in addition to twice daily use of conventional toothpaste.
Study NCT05710874 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional
Description: Twice daily use of conventional toothpaste.
Study NCT02569489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-8000
Study NCT02569489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT02569489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02031146 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar puncture
Study NCT03505866 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community home-based care intervention
Description: HIV-positive people who received community home-based care intervention on a monthly basis for six months after they enrolled in the program.
Study NCT00003641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: interferon alfa-2b
Description: Given IV
Study NCT00003641 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: observation
Description: Patients undergo observation for 4 weeks.
Study NCT02438072 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole (10 mg, A02BC01)
Description: The cocktail of drug substrates will be given one time, one day during the study, to explore the activity of CYP 1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and the P-gp
Study NCT03932136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane
Description: Sulforaphane (SFN) is a natural compound extracts from cruciferous vegetables, especially broccoli, with cytoprotective, anti-inflammatory, and antioxidant effects.
Study NCT01429935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules contain starch
Study NCT00795821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
Study NCT00795821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose: 3 tablets QD for 10 weeks
Study NCT02206893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring via Smartphone
Study NCT02206893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring via Smartphone
Study NCT02206893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support via Smartphone
Study NCT02206893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional support via Smartphone
Study NCT02206893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring via Web (Static)
Study NCT03922763 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical cut
Description: Surgeon-derived cut based on patient's anatomy
Study NCT03922763 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting guide
Description: Angle cut at 132.5 degrees based on cutting guide
Study NCT01843179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Up to two cycles. Administered via IV infusion on Days 1-5 of each 28 day cycle
Study NCT01843179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulindac
Description: Taken orally twice per day at home for 12 months
Study NCT03499353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALAZOPARIB
Description: Talazoparib 1mg/day
Study NCT00645853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od
Study NCT00645853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VKA INR 2-3
Description: Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5
Study NCT02145273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Depression -Group
Study NCT03406598 — intervention group
Intervention type: OTHER
Intervention: Patients in shock
Description: Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
Study NCT04221347 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: blood samples will be taken in specified time points
Study NCT03932136 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is safe, with no therapeutical effect, and has same appearance and similar smell and taste with active tablet.
Study NCT02129218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02129218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02129218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Dietary Intervention
Description: Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).